Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
152.6 DKK | +1.60% | -1.10% | +50.79% |
May. 30 | Alk's European Registration Application for Itulazax for Pneumiatric Indication Accepted for Review | CI |
May. 03 | Transcript : ALK-Abelló A/S, Q1 2024 Earnings Call, May 03, 2024 |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+50.79% | 4.91B | |
+40.73% | 739B | |
+32.83% | 598B | |
-6.30% | 353B | |
+15.15% | 318B | |
+4.05% | 285B | |
+15.00% | 240B | |
-5.52% | 206B | |
+6.17% | 164B | |
-0.45% | 162B |
- Stock Market
- Equities
- ALK B Stock
- News ALK-Abelló A/S
- ALK-Abelló President/CEO to Step Down at 2023-End; Successor Named